Rani Therapeutics Secures $1.7M Q1 Revenue, Extends Cash Runway to Q4 2027
RANI•Rani ended Q1 with $43.4M in cash and securities, down from $49.7M, and reported $1.7M contract revenue vs $0.2M a year earlier, projecting funding into Q4 2027. The company advanced its Phase 1 RT-114 obesity trial and appointed three senior leaders while initiating a CFO succession.
1. First Quarter Financial Results
Rani closed Q1 with $43.4 million in cash, cash equivalents and marketable securities, down from $49.7 million at year-end, and recorded $1.7 million in contract revenue versus $0.2 million a year earlier, driven by its Chugai collaboration. R&D expenses fell to $5.2 million from $6.6 million, and management expects existing funds plus an anticipated milestone payment to support operations into the fourth quarter of 2027.
2. Pipeline Advancement
The company continued its Phase 1 clinical trial of RT-114, an oral GLP-1/GLP-2 dual agonist delivered via the RaniPill® platform for obesity treatment in collaboration with ProGen, evaluating safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics across single and multiple doses.
3. Leadership Updates and CFO Transition
Rani promoted Alireza Javadi, Ph.D. to Chief Technical Officer, appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor, and announced CFO Svai Sanford will transition following the appointment of a successor, remaining through the handover to ensure continuity.
